Most Popular
1. It’s a New Macro, the Gold Market Knows It, But Dead Men Walking Do Not (yet)- Gary_Tanashian
2.Stock Market Presidential Election Cycle Seasonal Trend Analysis - Nadeem_Walayat
3. Bitcoin S&P Pattern - Nadeem_Walayat
4.Nvidia Blow Off Top - Flying High like the Phoenix too Close to the Sun - Nadeem_Walayat
4.U.S. financial market’s “Weimar phase” impact to your fiat and digital assets - Raymond_Matison
5. How to Profit from the Global Warming ClImate Change Mega Death Trend - Part1 - Nadeem_Walayat
7.Bitcoin Gravy Train Trend Forecast 2024 - - Nadeem_Walayat
8.The Bond Trade and Interest Rates - Nadeem_Walayat
9.It’s Easy to Scream Stocks Bubble! - Stephen_McBride
10.Fed’s Next Intertest Rate Move might not align with popular consensus - Richard_Mills
Last 7 days
Stock Market Brief in Count Down to US Election Result 2024 - 3rd Nov 24
Gold Stocks’ Winter Rally 2024 - 3rd Nov 24
Why Countdown to U.S. Recession is Underway - 3rd Nov 24
Stock Market Trend Forecast to Jan 2025 - 2nd Nov 24
President Donald PUMP Forecast to Win US Presidential Election 2024 - 1st Nov 24
At These Levels, Buying Silver Is Like Getting It At $5 In 2003 - 28th Oct 24
Nvidia Numero Uno Selling Shovels in the AI Gold Rush - 28th Oct 24
The Future of Online Casinos - 28th Oct 24
Panic in the Air As Stock Market Correction Delivers Deep Opps in AI Tech Stocks - 27th Oct 24
Stocks, Bitcoin, Crypto's Counting Down to President Donald Pump! - 27th Oct 24
UK Budget 2024 - What to do Before 30th Oct - Pensions and ISA's - 27th Oct 24
7 Days of Crypto Opportunities Starts NOW - 27th Oct 24
The Power Law in Venture Capital: How Visionary Investors Like Yuri Milner Have Shaped the Future - 27th Oct 24
This Points To Significantly Higher Silver Prices - 27th Oct 24
US House Prices Trend Forecast 2024 to 2026 - 11th Oct 24
US Housing Market Analysis - Immigration Drives House Prices Higher - 30th Sep 24
Stock Market October Correction - 30th Sep 24
The Folly of Tariffs and Trade Wars - 30th Sep 24
Gold: 5 principles to help you stay ahead of price turns - 30th Sep 24
The Everything Rally will Spark multi year Bull Market - 30th Sep 24
US FIXED MORTGAGES LIMITING SUPPLY - 23rd Sep 24
US Housing Market Free Equity - 23rd Sep 24
US Rate Cut FOMO In Stock Market Correction Window - 22nd Sep 24
US State Demographics - 22nd Sep 24
Gold and Silver Shine as the Fed Cuts Rates: What’s Next? - 22nd Sep 24
Stock Market Sentiment Speaks:Nothing Can Topple This Market - 22nd Sep 24
US Population Growth Rate - 17th Sep 24
Are Stocks Overheating? - 17th Sep 24
Sentiment Speaks: Silver Is At A Major Turning Point - 17th Sep 24
If The Stock Market Turn Quickly, How Bad Can Things Get? - 17th Sep 24
IMMIGRATION DRIVES HOUSE PRICES HIGHER - 12th Sep 24
Global Debt Bubble - 12th Sep 24
Gold’s Outlook CPI Data - 12th Sep 24

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

How to Ride the Surge in Biotech Mergers & Acquisitions

Companies / BioTech May 16, 2012 - 09:57 AM GMT

By: Money_Morning

Companies

Best Financial Markets Analysis ArticleDon Miller writes: Innovations in biotechnology are evolving at the speed of light.

In fact, astonishing advancements in biotech have transformed the way we practice medicine. Leading-edge biotech products and breakthroughs are literally saving thousands of lives every day.


Needless to say, biotech stocks can be strong medicine for investors, too.

For instance, the Nasdaq Biotechnology Index rose 457% from the end of August 1998 to the end of February 2000. Going back even further to the early 1990s, biotech stocks have soared by 1,347%.

Think about it... for biotech investors every $10,000 invested turned into nearly $140,000.

The good news for investors is that after slumping during the recession, biotech stocks are making a comeback. In the first quarter of 2012 alone, the Nasdaq Biotech Index gained 18.2%

And conditions are setting up for even better gains in the future.

Here's why...

M&A Drives Biotech Stocks Higher
While many biotech companies are riding high on new drugs, the recent surge in biotech stocks largely reflects a slew of mergers and acquisitions (M&A).

More importantly, more deals are likely on the horizon.

In fact, 91% of industry executives believe pharma-biotech mergers will increase in the next 10 years, according to imap.com.

You see, big pharmaceutical companies are losing their patents on lucrative blockbuster drugs and are about to lose billions of dollars in sales.

For instance, Pfizer Inc.'s (NYSE: PFE) cholesterol-lowering drug Lipitor earned the company a smooth $5 billion or so last year. And Bristol-Myers Squibb Co. (NYSE: BME) and Sanofi-Aventis SA (ADR NYSE: SNY) pocketed more than $6 billion in U.S. sales from the blood thinner Plavix.

However, both those patents have expired, opening the door for generic versions that could cost up to 80% less.

Fortunately for Big Pharma they're flush with cash, and the biotech sector is full of smaller biotech development companies with promising pipelines.

So instead of spending billions on years of research and testing to develop their own drugs, it only makes sense for big companies to swallow biotech companies with new products in advanced stages.

"The upside here is that large pharmaceuticals will continue to acquire these companies...They have tons of cash...which makes almost every publicly-traded biotech a target for someone," Josh Brown, a New York City-based investment advisor recently wrote.

The trend accelerated earlier this month when GlaxoSmithKline plc (NYSE: GSK) launched a hostile takeover for Human Genome Sciences (Nasdaq: HGSI), after HGSI rebuffed a $2.6 billion offer.

But large war chests also mean there's lots of competition to buy the best small companies with the most promising pipelines.

Reduce Guesswork with Biotech Stock ETFs
The current supply/demand squeeze sets up a perfect scenario for investors because it's likely to drive the price of acquisitions sky-high, according to Money Morning Executive Editor Bill Patalon, who spent years covering the biotech industry.

However, investing in biotech stocks requires not only an understanding of the company's finances, but also knowledge of the company's potential based on its products and technologies.

You can reduce some of the guesswork by using exchange-traded funds (ETFs), which give you exposure without betting the farm on a single company.

ETFs trade on major exchanges and expenses are generally lower than those of actively traded mutual funds.

Here are three biotech ETFs to consider:

•iShares Nasdaq Biotechnology Index ETF (Nasdaq: IBB): The "granddaddy" of biotech ETFs was established in 2001 and carries a market cap of nearly $1.8 billion, making it the largest in the category. IBB tracks the Nasdaq Biotechnology Index and focuses on big players like Amgen Inc.(Nasdaq: AMGN) andCelgene Corp. (Nasdaq CELG). Its expense ratio is 0.48%. One-year return is 28.4% and its year-to-date (YTD) return is nearly 17%.
•SPDR S&P Biotech ETF (NYSEArca: XBI): XBI holds 30 large and small biotech companies in equal weightings. That means smaller components have equal say in its overall performance. Accordingly, the fund got a nice boost after HGSI's stock jumped on the takeover bid. With a market cap of $518 million, its expense ratio is 0.35%. One-year return is over 26% and its YTD return is 18%.
•PowerShares Dynamic Biotechnology & Genome Portfolio ETF: (NYSEArca: PBE). This fund holds the usual large-caps like Amgen and Biogen Idec Inc. (Nasdaq: BIIB), but it also holds promising small companies including BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), and Seattle Genetics Inc. (Nasdaq: SGEN), which have drugs in late-stage testing. Admittedly, it's higher risk, but these companies could be appetizing targets for Big Pharma. With a market cap of $140 million, its expense ratio is 0.63%. It has a one-year return of over 8% and a year-to-date return of 12%.

[Editor's Note: Handicapping buyout targets is a tall order. But we've already done the hard work for you.

Best of all: We've identified three biotech firms that are likely on a lot of radar screens.

But because they're quality companies with substantial growth potential, they are stocks worth holding even if no deals materialize.

To find out how to get your copy of the new report "The Biotech Buyout Binge: Why These Three Stocks Could Double Your Money in the Next Three Months" - just click here.]

Source :http://moneymorning.com/2012/05/16/biotech-stock-etfs-how-to-ride-the-surge-in-biotech-mergers-acquisitions/

Money Morning/The Money Map Report

©2011 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in